Should I buy or sell Freeline Therapeutics stock right now?

2 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Freeline Therapeutics in the last twelve months. There are currently 2 hold ratings for the stock. The consensus among Wall Street research analysts is that investors should "hold" FRLN shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in FRLN, but not buy additional shares or sell existing shares. View FRLN analyst ratings or view top-rated stocks .

What is Freeline Therapeutics' stock price target for 2024?

2 brokerages have issued 12-month price objectives for Freeline Therapeutics' stock. Their FRLN share price targets range from $3.00 to $6.50. On average, they anticipate the company's stock price to reach $4.83 in the next twelve months. This suggests that the stock has a possible downside of 25.4%. View analysts price targets for FRLN or view top-rated stocks among Wall Street analysts .

How were Freeline Therapeutics' earnings last quarter?

Freeline Therapeutics Holdings plc (NASDAQ:FRLN) released its quarterly earnings results on Tuesday, November, 9th. The company reported ($12.90) earnings per share for the quarter, topping the consensus estimate of ($15.20) by $2.30.

When did Freeline Therapeutics' stock split?

Shares of Freeline Therapeutics reverse split on the morning of Friday, May 12th 2023. The 1-15 reverse split was announced on Friday, May 12th 2023. The number of shares owned by shareholders was adjusted after the market closes on Friday, May 12th 2023. An investor that had 100 shares of stock prior to the reverse split would have 7 shares after the split.

What other stocks do shareholders of Freeline Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Freeline Therapeutics investors own include Adobe (ADBE) , BigCommerce (BIGC) , Checkmate Pharmaceuticals (CMPI) , CVS Health (CVS) , Old Dominion Freight Line (ODFL) , Oak Street Health (OSH) , Rocket Companies (RKT) , Shopify (SHOP) , Zoom Video Communications (ZM) and Zymeworks (ZYME) .

When did Freeline Therapeutics IPO?

Freeline Therapeutics (FRLN) raised $126 million in an initial public offering (IPO) on Friday, August 7th 2020. The company issued 7,400,000 shares at a price of $16.00-$18.00 per share. J.P. Morgan, Morgan Stanley and Evercore ISI served as the underwriters for the IPO and Wedbush PacGrow was co-manager.

NASDAQ:FRLN

Freeline Therapeutics (FRLN) Stock Price, News & Analysis

→ The “Perfect Storm” for Gold (From Gold Safe Exchange) (Ad)

Free FRLN Stock Alerts

Notice: This company has been marked as potentially delisted and may not be actively trading.

Compare

Today's Range: $6.48
▼
$6.48
50-Day Range: $6.43
▼
$6.49
52-Week Range: $2.11
▼
$8.74

Volume: N/A
Average Volume: 12,055 shs
Market Capitalization: $28.12 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $4.83

Stock Analysis Analyst Forecasts Earnings Headlines Ownership Short Interest Social Media

Get Freeline Therapeutics alerts:

Freeline Therapeutics MarketRank™ Stock Analysis

Analyst Rating: Hold
2.00 Rating Score
Upside/Downside: 25.4% Downside
$4.83 Price Target
Short Interest: N/A
Dividend Strength: N/A
Sustainability: N/A
News Sentiment: N/A
Insider Trading: N/A
Proj. Earnings Growth: Growing
From ($1.01) to ($0.15) Per Share

Overall MarketRank^™

New Rank-Based ScoringMarketRank^™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

0.04 out of 5 stars

Medical Sector

915th out of 918 stocks

Biotechnology Industry

43rd out of 43 stocks

1.0

Analyst's Opinion

Consensus Rating
Freeline Therapeutics has received a consensus rating of Hold. The company's average rating score is 2.00, and is based on no buy ratings, 2 hold ratings, and no sell ratings.
Amount of Analyst Coverage
Freeline Therapeutics has received no research coverage in the past 90 days.

N/A

Short Interest

Short Interest
There is no current short interest data available for FRLN.

0.0

Dividend Strength

Dividend Yield
Freeline Therapeutics does not currently pay a dividend.
Dividend Growth
Freeline Therapeutics does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for FRLN.

0.0

News and Social Media Coverage

Search Interest
Only 1 people have searched for FRLN on MarketBeat in the last 30 days. This is a decrease of -50% compared to the previous 30 days.

0.8

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Freeline Therapeutics insiders have not sold or bought any company stock.
Percentage Held by Insiders
Only 1.90% of the stock of Freeline Therapeutics is held by insiders.
Percentage Held by Institutions
46.26% of the stock of Freeline Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

1.3

Earnings and Valuation

Earnings Growth
Earnings for Freeline Therapeutics are expected to grow in the coming year, from ($1.01) to ($0.15) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Freeline Therapeutics is -1.16, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Freeline Therapeutics is -1.16, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Freeline Therapeutics has a P/B Ratio of 0.54. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

Ad DTI

Biden’s $374B Giveaway Into This Sector

Biden’s Climate Bill Could Send Your Retirement Accounts Soaring – Or Diving See what this $374B giveaway could mean for your retirement right here

Click here for the full story

About Freeline Therapeutics Stock (NASDAQ:FRLN)

Freeline Therapeutics Holdings plc, a clinical-stage biotechnology company, develops transformative adeno-associated virus (AAV) vector-mediated gene therapies. It develops FLT180a for the treatment of hemophilia B.; FLT201 for the treatment of Type 1 Gaucher disease; and FLT190 for the treatment of Fabry disease. in addition, it has research programs for systemic gene therapy. The company was founded in 2015 and is headquartered in Stevenage, the United Kingdom.

Ad DTI

Biden’s $374B Giveaway Into This Sector

Biden’s Climate Bill Could Send Your Retirement Accounts Soaring – Or Diving See what this $374B giveaway could mean for your retirement right here

Click here for the full story

FRLN Stock News Headlines

February 25, 2024 | benzinga.com

Freeline Therapeutics Stock (NASDAQ:FRLN) Dividends: History, Yield and Dates

February 20, 2024 | finance.yahoo.com

Acquisition of Freeline by Syncona Becomes Effective

April 19, 2024 | DTI (Ad)

Biden’s $374B Giveaway Into This Sector

Biden’s Climate Bill Could Send Your Retirement Accounts Soaring – Or Diving See what this $374B giveaway could mean for your retirement right here

February 20, 2024 | globenewswire.com

Acquisition of Freeline by Syncona Becomes Effective

February 13, 2024 | finanznachrichten.de

Freeline Therapeutics Shareholders Approve Acquisition by Syncona

February 12, 2024 | finance.yahoo.com

Freeline Shareholders Approve Acquisition by Syncona

February 9, 2024 | uk.finance.yahoo.com

Freeline Therapeutics Holdings plc (FRLN)

December 1, 2023 | markets.businessinsider.com

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates SRC, EAR, PATI, FRLN

April 19, 2024 | DTI (Ad)

Biden’s $374B Giveaway Into This Sector

Biden’s Climate Bill Could Send Your Retirement Accounts Soaring – Or Diving See what this $374B giveaway could mean for your retirement right here

November 30, 2023 | markets.businessinsider.com

Analysts Have Conflicting Sentiments on These Healthcare Companies: Argenx Se (ARGX) and Freeline Therapeutics Holdings (FRLN)

November 29, 2023 | businesswire.com

FREELINE THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Freeline ...

November 23, 2023 | finance.yahoo.com

Freeline (FRLN) Shares Rise on Merger Agreement With Syncona

November 22, 2023 | finanznachrichten.de

Syncona Limited to Acquire Freeline Therapeutics

November 22, 2023 | tmcnet.com

FRLN Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Freeline Therapeutics Holdings plc Is Fair to Shareholders

November 18, 2023 | seekingalpha.com

FRLN Freeline Therapeutics Holdings plc

November 5, 2023 | morningstar.com

Freeline Therapeutics Holdings PLC ADR FRLN

October 28, 2023 | markets.businessinsider.com

Freeline Therapeutics: Promising Initial Efficacy Data and Potential for High Revenues Justify Buy Rating

October 25, 2023 | finance.yahoo.com

Freeline Presents Positive New Data from Phase 1/2 GALILEO-1 Trial of FLT201, Its Novel Gene Therapy Candidate, in Gaucher Disease at ESGCT 30th Annual Congress

October 19, 2023 | finance.yahoo.com

Here's Why We're A Bit Worried About Freeline Therapeutics Holdings' (NASDAQ:FRLN) Cash Burn Situation

October 18, 2023 | markets.businessinsider.com

Where Freeline Therapeutics Stands With Analysts

October 16, 2023 | finance.yahoo.com

Freeline to Present New Clinical Data for FLT201 in Gaucher Disease in Oral Presentation at Upcoming ESGCT 30th Annual Congress

October 6, 2023 | marketwatch.com

Freeline Therapeutics ADRs Rise 14% Following Positive Trial Data on FLT201

October 5, 2023 | markets.businessinsider.com

Promising Gaucher Disease Trial Results and Potential Parkinson’s Disease Impact Bolster Analyst’s Buy Rating for Freeline Therapeutics Holdings

October 4, 2023 | benzinga.com

Why Is Gene Therapy Player Freeline Therapeutics Stock Trading Higher Today?

October 4, 2023 | markets.businessinsider.com

Freeline Reports Positive Data From First Cohort Of Phase 1/2 GALILEO-1 Trial Of FLT201

October 4, 2023 | finance.yahoo.com

Freeline Reports Positive Initial Clinical Data from First Cohort of Phase 1/2 GALILEO-1 Trial of FLT201, Its Novel Gene Therapy Candidate, in Gaucher Disease

August 17, 2023 | markets.businessinsider.com

H.C. Wainwright Sticks to Their Buy Rating for Freeline Therapeutics Holdings (FRLN)

See More Headlines

Receive FRLN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Freeline Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 11/09/2021
Today: 4/18/2024
Fiscal Year End: 12/31/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Sector: Medical
Industry: Biotechnology
Sub-Industry: N/A
Current Symbol: NASDAQ:FRLN
CUSIP: N/A
CIK: 1810031
Web: www.freeline.life
Phone: 44-0-14-3890-6870
Fax: N/A
Employees: 152
Year Founded: N/A

Price Target and Rating

Average Stock Price Target: $4.83
High Stock Price Target: $6.50
Low Stock Price Target: $3.00
Potential Upside/Downside: -25.4%
Consensus Rating: Hold
Rating Score (0-4): 2.00
Research Coverage: 2 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($5.5939)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-88,970,000.00
Net Margins: N/A
Pretax Margin: N/A
Return on Equity: -150.46%
Return on Assets: -97.01%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 1.95
Quick Ratio: N/A

Sales & Book Value

Annual Sales: N/A
Price / Sales: N/A
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $12.07 per share
Price / Book: 0.54

Miscellaneous

Outstanding Shares: 4,340,000
Free Float: 4,259,000
Market Cap: $28.12 million
Optionable: Not Optionable
Beta: 0.66

12 Stocks Corporate Insiders are Abandoning

If a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know?

Get This Free Report

Key Executives

Mr. Michael J. Parini J.D. (Age 49)
CEO & Executive Director
Comp: $2.16M
Mr. Paul M. Schneider (Age 53)
CFO & Director
Dr. Henning R. Stennicke Ph.D. (Age 56)
Chief Scientific Officer
Ms. Nicole Jones SPHR (Age 53)
Chief People Officer
Mr. James Bircher (Age 56)
Chief Technical Operations Officer
Dr. Pamela Foulds M.D. (Age 54)
Chief Medical Officer
Ms. Naomi Aoki
Senior Vice President of Corporate Communications & Investor Relations
Ms. Amy J. Spandau (Age 49)
Interim Head of Finance

Key Competitors

View All Competitors

Institutional Ownership

View All Institutional Transactions

FRLN Stock Analysis - Frequently Asked Questions

Should I buy or sell Freeline Therapeutics stock right now?: 2 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Freeline Therapeutics in the last twelve months. There are currently 2 hold ratings for the stock. The consensus among Wall Street research analysts is that investors should "hold" FRLN shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in FRLN, but not buy additional shares or sell existing shares.
View FRLN analyst ratings or view top-rated stocks.
What is Freeline Therapeutics' stock price target for 2024?: 2 brokerages have issued 12-month price objectives for Freeline Therapeutics' stock. Their FRLN share price targets range from $3.00 to $6.50. On average, they anticipate the company's stock price to reach $4.83 in the next twelve months. This suggests that the stock has a possible downside of 25.4%.
View analysts price targets for FRLN or view top-rated stocks among Wall Street analysts.
How were Freeline Therapeutics' earnings last quarter?: Freeline Therapeutics Holdings plc (NASDAQ:FRLN) released its quarterly earnings results on Tuesday, November, 9th. The company reported ($12.90) earnings per share for the quarter, topping the consensus estimate of ($15.20) by $2.30.
When did Freeline Therapeutics' stock split?: Shares of Freeline Therapeutics reverse split on the morning of Friday, May 12th 2023. The 1-15 reverse split was announced on Friday, May 12th 2023. The number of shares owned by shareholders was adjusted after the market closes on Friday, May 12th 2023. An investor that had 100 shares of stock prior to the reverse split would have 7 shares after the split.

What other stocks do shareholders of Freeline Therapeutics own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Freeline Therapeutics investors own include Adobe (ADBE), BigCommerce (BIGC), Checkmate Pharmaceuticals (CMPI), CVS Health (CVS), Old Dominion Freight Line (ODFL), Oak Street Health (OSH), Rocket Companies (RKT), Shopify (SHOP), Zoom Video Communications (ZM) and Zymeworks (ZYME).
When did Freeline Therapeutics IPO?: Freeline Therapeutics (FRLN) raised $126 million in an initial public offering (IPO) on Friday, August 7th 2020. The company issued 7,400,000 shares at a price of $16.00-$18.00 per share. J.P. Morgan, Morgan Stanley and Evercore ISI served as the underwriters for the IPO and Wedbush PacGrow was co-manager.

This page (NASDAQ:FRLN) was last updated on 4/19/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

Freeline Therapeutics (FRLN) Stock Price, News & Analysis

Freeline Therapeutics MarketRank™ Stock Analysis

Overall MarketRank™

Analyst's Opinion

Short Interest

Short Interest

Dividend Strength

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score

News and Social Media Coverage

Search Interest

Company Ownership

Earnings and Valuation

About Freeline Therapeutics Stock (NASDAQ:FRLN)

FRLN Stock News Headlines

Company Calendar

Industry, Sector and Symbol

Price Target and Rating

Profitability

Debt

Sales & Book Value

Miscellaneous

Key Executives

Key Competitors

Institutional Ownership

FRLN Stock Analysis - Frequently Asked Questions

Overall MarketRank^™